How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.

July 29, 2015

Advances in Personalized Medicine and Immuno-oncology

Dr. Steve O’Day discusses the current state of cancer treatments, which focuses less on standard chemotherapy and has begun relying more on targeted therapies and immune-oncology.

November 24, 2014

How to Better Establish Clinical Utility for Tests in Personalized Medicine

Dr. Gary Palmer discusses the different profile of tumors and how to make findings as general as possible to better treat the patient.